Apr. 2 at 3:09 PM
Stifel spoke w/ Drs. Mitchell Geffner of the Children's Hospital LA & USC, Ahmed Khattab of Mt. Sinai, and lan Marshall of Rutgers to discuss the Congenital Adrenal Hyperplasia (CAH) Landscape
$NBIX $CRNX
Stifel said, "On Crenessity, the uptake commentary was positive but tempered: each physician has prescribed the drug (3, 3, and 6 TRx), but in general they intend to see how early experience goes before ramping up their use significantly. Projecting out, feedback on Crenessity was probably a little more conservative on pediatrics than we've heard from other docs (projecting around
~40% penetration in ~2 years), however feedback was more bullish than expected on adult uptake, where physicians see many of these patients being motivated to seek treatment.
On
$CRNX's atumeletant, feedback was generally positive with the caveat that the initial N is small.
Separately, for
$NBIX, we are reducing our 1Q Ingrezza est ., in line with management's cautious commentary at recent investor conferences."
